Beijing Science Sun Pharmaceutical Co., Ltd.

Equities

300485

CNE100002110

Pharmaceuticals

End-of-day quote Shenzhen S.E. 23:00:00 06/06/2024 BST 5-day change 1st Jan Change
6.53 CNY +5.32% Intraday chart for Beijing Science Sun Pharmaceutical Co., Ltd. -10.06% -38.34%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Beijing Science Sun Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Approves Cash Dividend for 2023 CI
Beijing Science Sun Pharmaceutical Co., Ltd. agreed to acquire 5.6664% stake in Suzhou Inhal Pharma Co., Ltd. from Ningbo Menovo Ruihe Equity Investment Partnership for CNY 10 million. CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend (Tax Included) for the Year 2023 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Announces Executive Changes CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Beijing Science Sun Pharmaceutical Co., Ltd.(XSEC:300485) added to S&P Global BMI Index CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Approves Final Dividend for 2022 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2022 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Lin Xuehua completed the acquisition of a 45% stake in Beijing Zhongrun Weiye Investment Co., Ltd. from Beijing Science Sun Pharmaceutical Co., Ltd. for CNY 6.6 million. CI
Science Sun Pharma Passes Inspection of Premises MT
Lin Xuehua intends to acquire 45% stake in Beijing Zhongrun Weiye Investment Co., Ltd. from Beijing Science Sun Pharmaceutical Co., Ltd. for CNY 6.65 million CI
Beijing Science Sun Pharmaceutical Co., Ltd.(XSEC:300485) dropped from S&P Global BMI Index CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Beijing Science Sun Pharmaceutical Co., Ltd.(XSEC:300485) added to S&P Global BMI Index CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Announces Cash Dividend for the Fiscal Year 2021, Payable on 31 May 2022 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Approves the Profit Distribution of Final Cash Dividend for the Year 2021 CI
Chart Beijing Science Sun Pharmaceutical Co., Ltd.
More charts
Beijing Science Sun Pharmaceutical Co., LTD. is a China-based company principally engaged in research, manufacture and sales of biological and biochemical pharmaceuticals. The Company' products can be divided into cardiovascular series, immune regulation series, nervous system series and other natural or biotech pharmaceuticals. Its products include small capacity injection and freeze-dried powder injection.
More about the company

Annual profits - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW